From: Drug utilization and cost associated with inflammatory bowel disease management in Saudi Arabia
Medication | CD (N = 258) | UC (N = 249) | P-value | Total (N = 507) |
---|---|---|---|---|
Biological agent, n (%) | Â | |||
 Infliximab | 95 (36.82) | 28 (11.24) | < 0.01* | 123 (24.26) |
 Adalimumab | 53 (20.54) | 24 (9.64) | < 0.01* | 77 (15.19) |
 Certolizumab | 6 (2.33) | 0 | 0.03 | 6 (1.18) |
 Golimumab | 0 | 1 (0.40) | 0.49 | 1 (0.20) |
 Ustekinumab | 4 (1.55) | 0 | 0.12 | 4 (0.79) |
 Vedolizumab | 2 (0.78) | 2 (0.80) | 1 | 4 (0.79) |
Non-biological agents, n (%) | Â | |||
 Azathioprine | 185 (71.71) | 100 (40.16) | < 0.01* | 285 (56.21) |
 Mercaptopurine | 0 | 3 (1.20) | 0.12 | 3 (0.59) |
 Methotrexate | 7 (2.71) | 0 | 0.02 | 7 (1.38) |
 Sulfasalazine | 3 (1.16) | 3 (1.20) | 1 | 6 (1.18) |
 Mesalazine | 37 (14.34) | 208 (83.53) | < 0.01* | 245 (48.32) |
 Prednisone | 0 | 0 | – | 0 |
 Prednisolone | 6 (2.33) | 12 (4.82) | 0.13 | 18 (3.55) |
 Hydrocortisone | 3 (1.16) | 3 (1.20) | 1 | 6 (1.18) |
 Budesonide | 9 (3.49) | 0 | 0.01* | 9 (1.78) |
 Corticosteroids | 18 (6.98) | 15 (6.02) | 0.66 | 33 (6.51) |
 Metronidazole | 12 (4.65) | 4 (1.61) | 0.03* | 16 (3.16) |
 Ciprofloxacin | 5 (1.94) | 4 (1.60) | 0.45 | 9 (1.78) |